Jazz Pharmaceuticals (JAZZ) Share-based Compensation (2010 - 2026)

Jazz Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $74.5 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 10.04% year-over-year to $74.5 million; the TTM figure through Mar 2026 stood at $297.9 million (up 17.16% YoY), while the FY2025 annual figure was $291.1 million, up 17.37% from the prior year.
• Share-based Compensation was $74.5 million for Q1 2026 at Jazz Pharmaceuticals, up from $70.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $88.1 million in Q3 2025 to a low of $50.1 million in Q1 2022.
• Historically, Share-based Compensation has averaged $62.5 million across 5 years, with a median of $61.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation decreased 14.0% in 2023, then jumped 47.46% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $61.6 million in 2022, then dropped by 14.0% to $52.9 million in 2023, then soared by 32.58% to $70.2 million in 2024, then climbed by 0.95% to $70.9 million in 2025, then increased by 5.15% to $74.5 million in 2026.
• The last three Share-based Compensation figures came in at $74.5 million (Q1 2026), $70.9 million (Q4 2025), and $88.1 million (Q3 2025), per Business Quant data.